Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry

Recurrent glioblastoma multiforme (GBM), insensitive against most therapeutic interventions, has low response and survival rates. Temozolomide (TMZ) was approved for second-line therapy of recurrent anaplastic astrocytoma. However, TMZ therapy in GBM patients reveals properties such as reduced toler...

Full description

Saved in:
Bibliographic Details
Published inDrug design, development and therapy Vol. 2; no. default; pp. 289 - 301
Main Author Braun, Klaus
Format Journal Article
LanguageEnglish
Published Macclesfield Taylor & Francis Ltd 01.01.2009
Dove Press
Dove Medical Press
Subjects
Astrocytoma
Brain
Brain cancer
Brain tumors
carrier molecules
Chemistry
Chemotherapy
Deprivation
Dosage
drug delivery
facilitated transport
Glioblastoma
Glioblastoma multiforme
Glioma cells
Organic chemistry
Pharmacology
Temozolomide
Therapeutic applications
Online AccessGet full text

Cover

More Information
Summary:Recurrent glioblastoma multiforme (GBM), insensitive against most therapeutic interventions, has low response and survival rates. Temozolomide (TMZ) was approved for second-line therapy of recurrent anaplastic astrocytoma. However, TMZ therapy in GBM patients reveals properties such as reduced tolerability and inauspicious hemogram. The solution addressed here concerning GBM therapy consolidates and uses the potential of organic and peptide chemistry with molecular medicine. We enhanced the pharmacologic potency with simultaneous reduction of unwanted adverse reactions of the highly efficient chemotherapeutic TMZ. The TMZ connection to transporter molecules (TMZ-BioShuttle) was investigated, resulting in a much higher pharmacological effect in glioma cell lines and also with reduced dose rate. From this result we can conclude that a suitable chemistry could realize the ligation of pharmacologically active, but sensitive and highly unstable pharmaceutical ingredients without functional deprivation. The TMZ-BioShuttle dramatically enhanced the potential of TMZ for the treatment of brain tumors and is an attractive drug for combination chemotherapy.
ISSN:1177-8881
1177-8881
DOI:10.2147/DDDT.S3572